Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP258813.RAns7X4kKC2ZUGQhfOM0wb3muA4NZZkpSFYAswmagqGKI130_provenance.
• NP536763.RAvqp7nRivZgktG1FbLLTWbJ-QpSJPXHabipww18VwMNg130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP536763.RAvqp7nRivZgktG1FbLLTWbJ-QpSJPXHabipww18VwMNg130_provenance.
• NP316744.RAxtVjqFlXokJO12NBTwYJfMHgPujXLi350efym5jxOL0130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP316744.RAxtVjqFlXokJO12NBTwYJfMHgPujXLi350efym5jxOL0130_provenance.
• NP217977.RAYuc05q-nYxJN9ayCiE8xa6GWuO7neWwpmkRwzCLyUC0130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217977.RAYuc05q-nYxJN9ayCiE8xa6GWuO7neWwpmkRwzCLyUC0130_provenance.
• NP693171.RAVesSlpjs6NKJuILPzRO8fs8a7sUCJr_e2Y868xo5SAQ130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP693171.RAVesSlpjs6NKJuILPzRO8fs8a7sUCJr_e2Y868xo5SAQ130_provenance.
• NP636752.RA5UsZA7q935EvBD3Lx5QUXF-8ApDV7f0Q7owB20GteOM130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP636752.RA5UsZA7q935EvBD3Lx5QUXF-8ApDV7f0Q7owB20GteOM130_provenance.
• NP682419.RA2ciLqwlRdyScapz3yUEgqa1sZxxix4YHlcCY9L9ky3Y130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP682419.RA2ciLqwlRdyScapz3yUEgqa1sZxxix4YHlcCY9L9ky3Y130_provenance.
• assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP516831.RAUed_pZmYT2NLucMt7zjkBaqrMz8YHNgboCDqFelX6jk130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP516831.RAUed_pZmYT2NLucMt7zjkBaqrMz8YHNgboCDqFelX6jk130_provenance.
• NP516832.RAYThfKwGpouHhZNK3Oxypt0TTU4BV2shVt4F0XLbnKoE130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP516832.RAYThfKwGpouHhZNK3Oxypt0TTU4BV2shVt4F0XLbnKoE130_provenance.
• NP516830.RAC9CETAFhcd1_diyNiBp3TFx8joHAXxex-UDw6ImdKWw130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP516830.RAC9CETAFhcd1_diyNiBp3TFx8joHAXxex-UDw6ImdKWw130_provenance.
• NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893925.RAOlcjgj2evmMr3vrDFRzFK3bUeLUdLjvl_Pu_Fxk3ioI130_provenance.
• NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
• NP217973.RAIHIzWZM4SNuQSFd_jAzsw6v41p536K97lVkRQCKSRx8130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217973.RAIHIzWZM4SNuQSFd_jAzsw6v41p536K97lVkRQCKSRx8130_provenance.
• NP693165.RAOLPxTf7iOdU-FiiE90kHznSgyFqq1v6dYtuRSCMHH5E130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP693165.RAOLPxTf7iOdU-FiiE90kHznSgyFqq1v6dYtuRSCMHH5E130_provenance.
• NP693167.RAGyYXStj202Ep52jddDWgG-_KqgDMDDnxuvdDGz4DqvE130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP693167.RAGyYXStj202Ep52jddDWgG-_KqgDMDDnxuvdDGz4DqvE130_provenance.
• NP516833.RALBJHuvZj-Yu_gsARH6JOBwsZrGJ8XdERoBkrYNmSiU8130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP516833.RALBJHuvZj-Yu_gsARH6JOBwsZrGJ8XdERoBkrYNmSiU8130_provenance.